Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KEAP1 mutant |
| Therapy | Radiotherapy + Telaglenastat |
| Indication/Tumor Type | lung adenocarcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KEAP1 mutant | lung adenocarcinoma | sensitive | Radiotherapy + Telaglenastat | Preclinical - Cell culture | Actionable | In a preclinical study, Telaglenstat (CB-839) increased sensitivity of a non-small cell lung cancer cell line harboring a KEAP1 mutation to radiotherapy in culture (PMID: 33071215). | 33071215 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (33071215) | KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. | Full reference... |